Company profile: Retrotope
1.1 - Company Overview
Company description
- Provider of a drug platform to preserve and restore mitochondrial health in degenerative diseases, developing isotopically stabilized fatty acid therapeutics to control metabolic processes linked to oxidative stress. Products include RT001, a clinical-stage isotopically stabilized synthetic linoleic acid for INAD, FA, ALS, and PSP, and RT011, an isotopically stabilized synthetic DHA advancing towards clinical trials for dry AMD.
Products and services
- Isotope-Effect Drug Platform: Architects a new therapeutic category that preserves and restores mitochondrial health by slowing damaging pathways and controlling oxidative-stress–associated metabolic processes using an isotope-effect-based approach
- RT001: Clinical-stage, isotopically stabilized synthetic linoleic acid (LA) engineered for treating orphan neurodegenerative diseases including INAD, FA, ALS, and PSP by preserving mitochondrial health and slowing damaging oxidative pathways
- RT011: Isotopically stabilized synthetic docosahexaenoic acid (DHA) advanced towards clinical trials for dry age-related macular degeneration (AMD), aiming to maintain mitochondrial health by slowing oxidative stress–driven damaging pathways.
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Retrotope
Vtesse Pharma
HQ: United States
Website
- Description: Provider of rare disease drug development for underserved patients, working collaboratively to advance VTS-270, which has shown promise in pre-clinical and clinical studies as a potential treatment for Niemann-Pick Disease; first spin-out of Cydan Development, Inc., an orphan-drug accelerator.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vtesse Pharma company profile →
Aspreva Pharmaceuticals
HQ: Canada
Website
- Description: Provider of pharmaceutical solutions focused on identifying, developing and commercializing new indications for approved drugs and drug candidates for underserved patient populations. Headquartered in Victoria, British Columbia, the company uses a collaboration strategy termed 'indication partnering'.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Aspreva Pharmaceuticals company profile →
Audentes Therapeutics
HQ: United States
Website
- Description: Provider of gene therapy research and development for rare muscle diseases, serving as the Gene Therapy Center of Excellence with divisions in technical operations, medical and development, and future commercialization of gene therapy programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Audentes Therapeutics company profile →
Wave Life Sciences
HQ: United States
Website
- Description: Provider of clinical-stage RNA medicines spanning RNA editing, antisense oligonucleotides, and RNA interference. Pipeline includes WVE-006 for alpha-1 antitrypsin deficiency, WVE-N531 for Duchenne muscular dystrophy, WVE-003 targeting the huntingtin gene to lower mutant huntingtin, and an INHBE program for obesity and metabolic disorders, advanced via the PRISM platform.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Wave Life Sciences company profile →
BioCryst
HQ: United States
Website
- Description: Provider of ORLADEYO (berotralstat), an oral plasma kallikrein inhibitor for prophylaxis to prevent hereditary angioedema attacks in adults and pediatric patients 12 years and older, and RAPIVAB (peramivir injection) for acute uncomplicated influenza; also developing BCX10013 (oral Factor D inhibitor) and an oral C5 inhibitor for complement-mediated diseases, BCX17725 for Netherton syndrome, and avoralstat for diabetic macular edema.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full BioCryst company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Retrotope
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Retrotope
2.2 - Growth funds investing in similar companies to Retrotope
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Retrotope
4.2 - Public trading comparable groups for Retrotope
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →